Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538 ...
Micromet announced updated results from a Phase 2 trial of blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). This multi-center ...
GAITHERSBURG, Md. and CARLSBAD, Calif., Aug. 21, 2006 (PRIMEZONE) -- MedImmune, Inc. (Nasdaq:MEDI) and Micromet, Inc. (Nasdaq:MITI) today announced that MedImmune has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results